Study study type PathologyT1T0Patientssample sizesROB Results

metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)

versus docetaxel
sotorasib
CodeBreaK 200, 2022
 
NCT04303780
RCTmetastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)oral sotorasib (960 mg daily)intravenous docetaxel (75 mg/m2 every 3 weeks)KRAS G12C-mutated NSCLC who progressed after prior platinum-based chemotherapy and a checkpoint inhibitor169 / 151NA
conclusif
  • demonstrated 34 % decrease in progression or deaths (PFS) (PE)
sotorasib NICE ITC 1 unpublished INDmetastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)sotorasibdocetaxel monotherapySLECT 1 patients with KRASmutated (including KRAS p.G12C -mutated) NSCLC-/-NA
suggested
  • suggested 40 % decrease in deaths (OS)
  • suggested 59 % decrease in progression or deaths (PFS)
sotorasib NICE ITC Flatiron unpublished INDmetastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)sotorasibdocetaxel monotherapy-/-NA
suggested
  • suggested 37 % decrease in deaths (OS)
versus no control (uncontrolled study)
sotorasib
CodeBreaK 100, 2021
  NCT03600883
DESCKRAS gene alteration defined cancer, metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)otorasib, administered orally at a dose of 960 mg once dailypatients with KRAS p.G12C-mutated advanced NSCLC previously treated with standard therapies124NA
no results
    no results
trametinib plus dabrafenib
BRF113928 unpublished
 
NCT01336634
NRametastatic/advanced NSCLC (mNSCLC) - 2nd line (L2)dabrafenib (150 mg orally twice daily) and trametinib (2 mg orally once daily)patients with locally confirmed BRAF V600E mutation-positive metastatic NSCLC-/-NA
no results
    no results